Brain damage markers neuron-specific enolase (NSE) and S100B in serum in children with Lyme neuroborreliosis-detection and evaluation as prognostic biomarkers for clinical outcome.
Biomarkers
Brain damage markers
Clinical outcome
Lyme neuroborreliosis
NSE
S100B
Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
25
02
2022
accepted:
16
05
2022
pubmed:
7
6
2022
medline:
7
7
2022
entrez:
6
6
2022
Statut:
ppublish
Résumé
Lyme borreliosis (LB) is the most common tick-borne infection in Europe, with Lyme neuroborreliosis (LNB) its second most frequent clinical manifestation. Prognostic factors for clinical outcomes in LNB have not been identified. Elevated serum levels of the brain damage markers neuron-specific enolase (NSE) and S100 calcium-binding protein B (S100B) have been associated with poor clinical outcomes in other disorders of the central nervous system. The aim of this study is to assess NSE and S100B in serum as prognostic biomarkers for clinical outcomes in paediatric LNB patients. Children evaluated for LNB (n = 121) in Sweden were prospectively included during 2010-2014, serum samples were collected on admission, and all children underwent a 2-month follow-up. Patients with pleocytosis and anti-Borrelia antibodies in cerebrospinal fluid (CSF) were classified as having LNB (n = 61). Controls were age- and gender-matched non-LNB patients (n = 60). NSE was elevated in 38/61 (62%) LNB patients and in 31/60 (52%) controls. S100B was elevated in 3/60 (5%) LNB patients and 0/59 (0%) controls. NSE and S100B concentrations did not differ significantly when comparing LNB patients with controls. No differences were found in the concentrations when comparing the clinical recovery of LNB patients at the 2-month follow-up. NSE was detectable in the majority of LNB patients and controls, whereas S100B was detectable in only a few LNB patients and no controls. NSE and S100B in serum cannot be recommended as prognostic biomarkers for clinical outcomes in children with LNB.
Identifiants
pubmed: 35665437
doi: 10.1007/s10096-022-04460-1
pii: 10.1007/s10096-022-04460-1
pmc: PMC9250468
doi:
Substances chimiques
Biomarkers
0
S100 Calcium Binding Protein beta Subunit
0
S100B protein, human
0
Phosphopyruvate Hydratase
EC 4.2.1.11
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1051-1057Subventions
Organisme : Centrum fÖr Klinisk Forskning Dalarna
ID : CKFUU-105141
Organisme : Centrum fÖr Klinisk Forskning Dalarna
ID : CKFUU-374651
Organisme : Centrum fÖr Klinisk Forskning Dalarna
ID : CKFUU-566761
Organisme : Svenska Läkaresällskapet
ID : SLS-498901
Organisme : Svenska Läkaresällskapet
ID : SLS-93191
Organisme : Landstinget i Uppsala län
ID : RFR-226161
Organisme : Landstinget i Uppsala län
ID : RFR-462701
Informations de copyright
© 2022. The Author(s).
Références
Front Biosci. 2002 May 01;7:d1356-68
pubmed: 11991838
Clin Microbiol Infect. 2011 Jan;17(1):69-79
pubmed: 20132258
Eur J Neurol. 2010 Jan;17(1):8-16, e1-4
pubmed: 19930447
Infection. 1996 Mar-Apr;24(2):125-9
pubmed: 8740104
BMC Pediatr. 2018 Jun 11;18(1):189
pubmed: 29890951
Clin Chem Lab Med. 2008;46(9):1296-9
pubmed: 18785867
Eur J Clin Microbiol Infect Dis. 2017 Nov;36(11):2221-2229
pubmed: 28730535
N Engl J Med. 1995 Nov 16;333(20):1319-27
pubmed: 7566023
Pediatr Infect Dis J. 2008 Dec;27(12):1089-94
pubmed: 19008771
Childs Nerv Syst. 2019 Feb;35(2):343-348
pubmed: 30171330
Lancet. 2003 Nov 15;362(9396):1639-47
pubmed: 14630446
Scand J Infect Dis. 2002;34(6):421-5
pubmed: 12160168
PLoS One. 2010 Sep 10;5(9):
pubmed: 20844757
Clin Chim Acta. 1984 Jan 31;136(2-3):219-28
pubmed: 6692576
Science. 1978 Jan 20;199(4326):313-5
pubmed: 339349
Clin Chem. 2014 Jun;60(6):823-34
pubmed: 24170612
Pediatr Infect Dis J. 2017 Nov;36(11):1052-1056
pubmed: 28654563
Neurology. 1995 Sep;45(9):1663-70
pubmed: 7675224
Clin Chem Lab Med. 2016 May;54(5):833-42
pubmed: 26479347
J Neurochem. 1980 May;34(5):1254-8
pubmed: 7373305
Expert Rev Anti Infect Ther. 2010 Apr;8(4):455-63
pubmed: 20377339
Pediatrics. 2012 Aug;130(2):262-9
pubmed: 22802606
Clin Chem. 2004 May;50(5):941-4
pubmed: 15105355
Neurocrit Care. 2018 Feb;28(1):26-34
pubmed: 28612133
Ann Neurol. 1991 Aug;30(2):197-205
pubmed: 1897911
J Neurotrauma. 2007 Dec;24(12):1793-801
pubmed: 18159990
Crit Care Med. 2004 Jan;32(1):131-6
pubmed: 14707571
J Neurol Sci. 1983 Aug-Sep;60(3):443-51
pubmed: 6355398
Eur J Neurol. 1999 Mar;6(2):169-78
pubmed: 10053229
An Pediatr (Barc). 2016 May;84(5):254-9
pubmed: 26589475
Scand J Clin Lab Invest. 1977 Sep;37(5):385-90
pubmed: 337459
Clin Chem. 2002 Jun;48(6 Pt 1):950-2
pubmed: 12029017